Centre Proposes Prior Central Approval for Antimicrobial Manufacturing

Conceptual microscope, generic medicine packages and a review document representing antimicrobial regulatory scrutiny.

NEW DELHI, November 19: Manufacturers of antimicrobial products would have to secure permission from the Central Licensing Authority before applying for a state manufacturing licence under a proposed change outlined by the Union Health Ministry today.

Conceptual microscope, generic medicine packages and a review document representing antimicrobial regulatory scrutiny.
AI-generated representative image. Conceptual regulatory review; not an image of a particular medicine, test or laboratory.

The November 19 ministry statement says the draft would include antimicrobials within the definition of a new drug under the New Drugs and Clinical Trials Rules, 2019. It identifies a draft Gazette notification dated November 6 as the basis for the proposal.

Two stages of regulatory scrutiny

The proposed sequence puts central permission ahead of an application to the relevant State Licensing Authority. The announcement describes a change to regulatory oversight; it does not say that the amendment has already been finalised.

The ministry links the proposal to concerns about manufacturing licences being granted without adequate scrutiny of supporting studies. It specifically refers to bioavailability, bioequivalence and stability assessments as areas requiring attention.

Why the ministry cites resistance

According to the ministry, inadequate assessment can affect product quality, safety and efficacy. It says substandard or ineffective antimicrobial products can contribute to the development and spread of antimicrobial resistance, with consequences for patient safety.

The proposed oversight change was also reported by IANS, carried by Ommcom News on November 19. The expected benefits remain the government’s stated rationale for the draft.

Comments are invited

The notice invites objections and suggestions before finalisation. Submissions may be sent to the Under Secretary (Drugs), Health Ministry, or drugsdiv-mohfw@gov.in, within 30 days of copies of the relevant Gazette being made available to the public.

Read more health governance and public policy reporting in our National section.

Photo: AI-generated representative image. Conceptual regulatory review; not an image of a particular medicine, test or laboratory.